Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

37 results
Display

Use of imatinib mesylate in a dog with meningoencephalitis of unknown etiology

Song JH, Jung DI

A 4-year-old, female, Maltese dog with bilateral hind limb ataxia was brought to Gyeongsang National University Animal Medical Center (GAMC). Based on the previous medical and imaging records, the patient...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gastric Gastrointestinal Stromal Tumor with Repeated Recurrence at the Anastomosis Site in a Very Elderly Patient

Kim HJ, Park JY, Kim BJ, Kim JG, Kim HS, Park JM

Although high-risk gastrointestinal stromal tumors (GISTs) frequently recur, even after a complete resection and imatinib therapy, local recurrence at the suture line after complete resection is rare. The present case...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Factors Influencing Imatinib-Induced Hepatotoxicity

Han JM, Yee J, Cho YS, Gwak HS

Purpose Although imatinib-induced hepatotoxicity may aggravate the patient’s clinical condition and alter the treatment plan, the underlying mechanism of and factors influencing imatinibinduced hepatotoxicity have rarely been investigated. The purpose of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Neuroprotective potential of imatinib in global ischemia-reperfusion-induced cerebral injury: possible role of Janus-activated kinase 2/signal transducer and activator of transcription 3 and connexin 43

Wang J, Bai T, Wang N, Li H, Guo X

The present study was aimed to explore the neuroprotective role of imatinib in global ischemia-reperfusion-induced cerebral injury along with possible mechanisms. Global ischemia was induced in mice by bilateral carotid...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor

Kang MK, Lee HJ, Choi JH

Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare. Its features vary from subclinical elevation...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib

Kim DS, Lee S, Choi CW

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor

Yim E, An HJ, Cho U, Kim Y, Kim SH, Choi YG, Shim BY

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor

Park EH, Kim JI, Cheung DY, Park SH

Gastrointestinal stromal tumor (GIST) is a mesenchymal tumor derived from Cajal cells originating from the myotonic plexus. The expression of tyrosine kinase (KIT) membrane receptors that are active on KIT...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A rare case of osteonecrosis of the jaw related to imatinib

Viviano M, Rossi M, Cocca S

Osteonecrosis of the jaw (ONJ) is commonly described as an adverse effect of the use of bisphosphonates. A few cases of ONJ associated with tyrosine kinase inhibitors (sunitinib, imatinib) have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Myeloid Neoplasm with a PDGFRB Rearrangement and Eosinophilia

Cho NG, Kim D, Shim M, Chong SY

Myeloid neoplasia with eosinophilia and platelet-derived growth factor receptor beta (PDGFRB) rearrangements is an uncommon Philadelphia-negative myeloproliferative neoplasm. Their most common morphological diagnosis is chronic myelomonocytic leukemia with eosinophilia, which...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Lichenoid Drug Eruption Associated with Imatinib Mesylate

Seol JE, Park SH, Kim DH, Kim H, Kang JN

  • KMID: 2396849
  • Korean J Dermatol.
  • 2017 Nov;55(9):621-622.
No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets

Arora R, Sharma M, Monif T, Iyer S

PURPOSE: This study was designed to characterize the pharmacokinetic profile and to assess bioequivalence of the sponsor's test formulation (imatinib mesylate 400 mg tablets) with an innovator product (Gleevec 400...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor

Koo DH, Ryu MH, Kim KM, Yang HK, Sawaki A, Hirota S, Zheng J, Zhang B, Tzen CY, Yeh CN, Nishida T, Shen L, Chen LT, Kang YK

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors originating in the gastrointestinal tract. With the introduction of molecular-targeted therapy for GISTs which has yielded remarkable outcomes, these tumors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection

Lee NR, Jang JW, Kim HS, Yhim HY

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Imatinib-induced Psoriasiform Drug Eruption in a Patient with a Gastrointestinal Stromal Tumor

Lee YJ, Lee WJ, Chang S, Lee MW, Choi JH, Moon KC

  • KMID: 2246088
  • Korean J Dermatol.
  • 2015 Jun;53(5):388-391.
Imatinib mesylate (Gleevec(R)) is a small-molecule inhibitor that selectively inhibits the tyrosine kinase family, including mutated KIT oncoproteins in gastrointestinal stromal tumors (GIST). However, cutaneous reactions to imatinib are common...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Correlation between Computed Tomography and Pathological Findings of Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate

Sim KC, Park BJ, Han NY, Sung DJ, Kim MJ, Cho SB, Ha HK, Kim HR

PURPOSE: To evaluate the correlation between pathological and computed tomography (CT) findings of gastrointestinal stromal tumors (GISTs) after imatinib mesylate (imatinib) treatment. MATERIALS AND METHODS: Twenty-six patients with GIST (17 men,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia

Oh HJ, Cho MS, Lee JW, Jang PS, Chung NG, Cho B, Kim HK

PURPOSE: Despite the established role of imatinib (IM) in chronic myelogenous leukemia (CML) in adults, there are few reports on its efficacy in children. In this study, we compared the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Inhibition of intimal hyperplasia by local perivascular application of rapamycin and imatinib mesilate after carotid balloon injury

Park D, Kim SM, Min SI, Ha J, Kim IG, Min SK

PURPOSE: Inhibition of the intimal hyperplasia after vascular surgery is an important issue. The purpose of this study is to define whether perivascular application of rapamycin, imatinib mesylate or cysteamine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Imatinib Mesylate Induced Acquired Dermal Melanocytosis

Kim EK, Jung KE, Kim HS, Park YM, Kim HO, Lee JY

  • KMID: 2301602
  • Korean J Dermatol.
  • 2012 Aug;50(8):747-750.
Dermal melanocytosis is most commonly found in the skin of Asians and other darkly pigmented populations. It is histologically characterized by the presence of ectopic melanocytes in the dermis. Mongolian...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Imatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients

Kim TH, Kim BG, Cho SW, Cho SK, Kim HJ, Yuh YJ, Kim SR

  • KMID: 2319555
  • Tuberc Respir Dis.
  • 2011 Sep;71(3):210-215.
Imatinib mesylate, a selective inhibitor of BCR-ABL kinase activity, has demonstrated significant clinical efficacy in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It has become...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr